INTRATHECAL ADMINISTRATION OF I-131 RADIOLABELED MONOCLONAL-ANTIBODY AS A TREATMENT FOR NEOPLASTIC MENINGITIS

被引：53

作者：

MOSELEY, RP

DAVIES, AG

RICHARDSON, RB

ZALUTSKY, M

CARRELL, S

FABRE, J

SLACK, N

BULLIMORE, J

PIZER, B

PAPANASTASSIOU, V

KEMSHEAD, JT

COAKHAM, HB

LASHFORD, LS

机构：

[1] FRENCHAY HOSP, IMPERIAL CANC RES FUND, PAEDIAT & NEUROONCOL GRP, BRISTOL BS16 1LE, AVON, ENGLAND

[2] FRENCHAY HOSP, DEPT NEUROSURG, BRAIN TUMOUR RES LAB, BRISTOL BS16 1LE, AVON, ENGLAND

[3] FRENCHAY HOSP, DEPT NUCL MED, BRISTOL BS16 1LE, AVON, ENGLAND

[4] DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA

[5] LUDWIG INST CANC RES, CH-1066 EPALINGES, SWITZERLAND

[6] E GRINSTEAD MED RES TRUST, BLOND MCINDOE CTR MED RES, E GRINSTEAD RH19 3DZ, W SUSSEX, ENGLAND

[7] BRISTOL ROYAL INFIRM & GEN HOSP, BRISTOL BS2 8HW, AVON, ENGLAND

来源：

BRITISH JOURNAL OF CANCER | 1990年 / 62卷 / 04期

关键词：

D O I：

10.1038/bjc.1990.345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months. © Macmillan Press Ltd., 1990.

引用

页码：637 / 642

页数：6

共 34 条

[1]

AGGI GLB, 1985, CANCER RES, V45, P3378

[2] BIOLOGICAL CHARACTERIZATION AND CLINICAL-APPLICATIONS OF A MONOCLONAL-ANTIBODY RECOGNIZING AN ANTIGEN RESTRICTED TO NEUROECTODERMAL TISSUES [J].